Latham & Watkins Advises Underwriters in Flexion Therapeutics’ Public Offering of Common Stock

New York-based team represented the underwriter in the biopharmaceutical company’s offering.

May 21, 2020

Flexion Therapeutics, Inc. has announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at a price to the public of US$9.75 per share. The gross proceeds from this offering are expected to be approximately US$90 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Flexion. The offering is expected to close on or about May 26, 2020, subject to customary closing conditions. Flexion has also granted the underwriters a 30-day option to purchase up to 1,384,615 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by New York partner Nathan Ajiashvili, with associates Sami Ghneim, Thomas Gabay, and Daniel Grill.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.